Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Algernon Pharmaceuticalsinc (AGN.CN)

Algernon Pharmaceuticalsinc (AGN.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Algernon Pharmaceuticalsinc 601 West Broadway Suite 400 Vancouver BC V5Z 4C2 CAN

https://www.algernonpharmaceuticals.com P: 604-398-4175

Description:

Algernon Pharmaceuticals Inc is a clinical-stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis and chronic cough. The company's business model is capital efficient and strives to deliver maximum shareholder value. Algernon's approach to drug discovery is based on the concept of drug repurposing. It operates in two reportable segments: the development of repurposed therapeutic drugs in Canada, and the facilitation of the Company's drug candidates into off-label phase II clinical trials (humans) in Australia.

Key Statistics

Overview:

Market Capitalization, $K 2,597
Shares Outstanding, K 21,641
Annual Sales, $ 0 K
Annual Net Income, $ -6,781 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -522 K
60-Month Beta 1.20
% of Institutional Shareholders 0.00%

Growth:

1-Year Return -61.67%
3-Year Return -97.26%
5-Year Return -98.00%
5-Year Revenue Growth 0.00%

Per-Share Information:

Latest Earnings Date N/A
Earnings Per Share ttm -0.28
EPS Growth vs. Prev Year -43.66%
Dividend Payout Ratio 0.00%
Most Recent Split 4-1 on 03/03/23

AGN.CN Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -199.05%
Return-on-Assets % -102.08%
Profit Margin % 0.00%
Debt/Equity N/A
Price/Sales N/A
Price/Book 2.56
Book Value/Share 0.05
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar